Vigabatrin - sanofi-aventis

Drug Profile

Vigabatrin - sanofi-aventis

Alternative Names: Gamma-vinyl-GABA; GVG; M071754; MDL 71754; RMI 71754; Sabril; Sabrilex; γ-vinyl-GABA

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Alfresa Pharma Corporation; Lundbeck Inc; National Institute on Drug Abuse; Sanofi; sanofi-aventis
  • Class Aminobutyric acids; Antiepileptic drugs; Small molecules
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Infantile spasms
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Complex partial epilepsy; Epilepsy; Infantile spasms
  • Discontinued Cocaine abuse; Drug abuse

Most Recent Events

  • 23 Jun 2016 The US FDA approves the modified Risk Evaluation and Mitigation Strategy (REMS) for vigabatrin
  • 01 Sep 2015 Discontinued - Phase-I for Drug abuse (Methamphetamine abuse) in USA (PO)
  • 01 Sep 2015 Discontinued - Phase-II for Cocaine abuse in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top